US equities
|
MU
$900.21
▼-3.33%
TSLA
$356.92
▼-1.52%
NVDA
$217.11
▼-0.06%
AAPL
$344.10
▲+0.61%
SPCX
$145.98
▼-1.78%
META
$717.18
▼-2.65%
SNDK
$1,336.67
▼-4.17%
MSFT
$528.05
▼-2.11%
MU
$900.21
▼-3.33%
TSLA
$356.92
▼-1.52%
NVDA
$217.11
▼-0.06%
AAPL
$344.10
▲+0.61%
SPCX
$145.98
▼-1.78%
META
$717.18
▼-2.65%
SNDK
$1,336.67
▼-4.17%
MSFT
$528.05
▼-2.11%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Cosmos Health Inc. - Common Stock
(NQ:
COSM
)
0.3359
-0.0041 (-1.21%)
Delayed Quote
Updated: 12:35 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cosmos Health Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
May 21, 2026
Via
ACCESS Newswire
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
May 14, 2026
Via
ACCESS Newswire
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
May 12, 2026
Via
ACCESS Newswire
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
May 11, 2026
Via
ACCESS Newswire
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
May 08, 2026
Via
ACCESS Newswire
Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
May 06, 2026
Via
ACCESS Newswire
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
April 30, 2026
Via
ACCESS Newswire
Top movers in Friday's after hours session
↗
April 24, 2026
Via
Chartmill
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
April 21, 2026
Via
ACCESS Newswire
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
April 20, 2026
Via
ACCESS Newswire
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
April 17, 2026
Via
ACCESS Newswire
Curious about the stocks that are showing activity after the closing bell on Thursday?
↗
April 16, 2026
Via
Chartmill
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
April 16, 2026
Via
ACCESS Newswire
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into
April 15, 2026
Via
ACCESS Newswire
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units
April 13, 2026
Via
ACCESS Newswire
Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
April 10, 2026
Via
ACCESS Newswire
Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
April 01, 2026
Via
ACCESS Newswire
Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue
March 19, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000
March 11, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
March 10, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
February 24, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value
February 19, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK’s Second-Largest Beauty and Health Retailer
February 18, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer
February 18, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026
February 17, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Expands Digital Assets Program with $500,000 Bitcoin Purchase, Bringing Total Cryptocurrency Investments to $2.5 Million; Evaluates Inclusion of Other Select Cryptocurrencies
February 11, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
January 20, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research
January 14, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units
January 05, 2026
From
Cosmos Health Inc.
Via
GlobeNewswire
Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy
December 24, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
